#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=The World Health Organisation recommends exclusive breastfeeding for infants up to six months of age , based on the clear health benefits of breastfeeding on mother-infant dyad .
2-1	16-19	The	organization[2]	new[2]	_	_
2-2	20-25	World	organization[2]	new[2]	_	_
2-3	26-32	Health	organization[2]	new[2]	_	_
2-4	33-45	Organisation	organization[2]	new[2]	_	_
2-5	46-56	recommends	_	_	_	_
2-6	57-66	exclusive	abstract[3]	new[3]	coref	5-4[0_3]
2-7	67-80	breastfeeding	abstract[3]	new[3]	_	_
2-8	81-84	for	abstract[3]	new[3]	_	_
2-9	85-92	infants	abstract[3]|person[4]	new[3]|new[4]	coref	4-1[16_4]
2-10	93-95	up	abstract[3]|person[4]|time[5]	new[3]|new[4]|new[5]	coref	6-29[38_5]
2-11	96-98	to	abstract[3]|person[4]|time[5]	new[3]|new[4]|new[5]	_	_
2-12	99-102	six	abstract[3]|person[4]|time[5]	new[3]|new[4]|new[5]	_	_
2-13	103-109	months	abstract[3]|person[4]|time[5]	new[3]|new[4]|new[5]	_	_
2-14	110-112	of	abstract[3]|person[4]|time[5]	new[3]|new[4]|new[5]	_	_
2-15	113-116	age	abstract[3]|person[4]|time[5]|abstract	new[3]|new[4]|new[5]|new	_	_
2-16	117-118	,	_	_	_	_
2-17	119-124	based	_	_	_	_
2-18	125-127	on	_	_	_	_
2-19	128-131	the	abstract[8]	new[8]	coref	6-2[30_8]
2-20	132-137	clear	abstract[8]	new[8]	_	_
2-21	138-144	health	abstract|abstract[8]	new|new[8]	_	_
2-22	145-153	benefits	abstract[8]	new[8]	_	_
2-23	154-156	of	abstract[8]	new[8]	_	_
2-24	157-170	breastfeeding	abstract[8]	new[8]	_	_
2-25	171-173	on	abstract[8]	new[8]	_	_
2-26	174-187	mother-infant	abstract[8]|abstract[9]	new[8]|new[9]	coref	15-19[127_9]
2-27	188-192	dyad	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-28	193-194	.	_	_	_	_

#Text=Indeed , there is a consensus regarding the association of breastfeeding with a reduced risk of respiratory and gastro-intestinal infections during the first year of life .
3-1	195-201	Indeed	_	_	_	_
3-2	202-203	,	_	_	_	_
3-3	204-209	there	_	_	_	_
3-4	210-212	is	_	_	_	_
3-5	213-214	a	abstract[10]	new[10]	_	_
3-6	215-224	consensus	abstract[10]	new[10]	_	_
3-7	225-234	regarding	abstract[10]	new[10]	_	_
3-8	235-238	the	abstract[10]|abstract[11]	new[10]|new[11]	_	_
3-9	239-250	association	abstract[10]|abstract[11]	new[10]|new[11]	_	_
3-10	251-253	of	abstract[10]|abstract[11]	new[10]|new[11]	_	_
3-11	254-267	breastfeeding	abstract[10]|abstract[11]	new[10]|new[11]	_	_
3-12	268-272	with	abstract[10]|abstract[11]	new[10]|new[11]	_	_
3-13	273-274	a	abstract[10]|abstract[11]|abstract[12]	new[10]|new[11]|new[12]	coref	4-13[18_12]
3-14	275-282	reduced	abstract[10]|abstract[11]|abstract[12]	new[10]|new[11]|new[12]	_	_
3-15	283-287	risk	abstract[10]|abstract[11]|abstract[12]	new[10]|new[11]|new[12]	_	_
3-16	288-290	of	abstract[10]|abstract[11]|abstract[12]	new[10]|new[11]|new[12]	_	_
3-17	291-302	respiratory	abstract[10]|abstract[11]|abstract[12]|event[13]	new[10]|new[11]|new[12]|new[13]	_	_
3-18	303-306	and	abstract[10]|abstract[11]|abstract[12]|event[13]	new[10]|new[11]|new[12]|new[13]	_	_
3-19	307-324	gastro-intestinal	abstract[10]|abstract[11]|abstract[12]|event[13]	new[10]|new[11]|new[12]|new[13]	_	_
3-20	325-335	infections	abstract[10]|abstract[11]|abstract[12]|event[13]	new[10]|new[11]|new[12]|new[13]	_	_
3-21	336-342	during	abstract[10]|abstract[11]|abstract[12]|event[13]	new[10]|new[11]|new[12]|new[13]	_	_
3-22	343-346	the	abstract[10]|abstract[11]|abstract[12]|event[13]|time[14]	new[10]|new[11]|new[12]|new[13]|new[14]	_	_
3-23	347-352	first	abstract[10]|abstract[11]|abstract[12]|event[13]|time[14]	new[10]|new[11]|new[12]|new[13]|new[14]	_	_
3-24	353-357	year	abstract[10]|abstract[11]|abstract[12]|event[13]|time[14]	new[10]|new[11]|new[12]|new[13]|new[14]	_	_
3-25	358-360	of	abstract[10]|abstract[11]|abstract[12]|event[13]|time[14]	new[10]|new[11]|new[12]|new[13]|new[14]	_	_
3-26	361-365	life	abstract[10]|abstract[11]|abstract[12]|event[13]|time[14]|abstract	new[10]|new[11]|new[12]|new[13]|new[14]|new	_	_
3-27	366-367	.	_	_	_	_

#Text=Infants , who were breastfed for longer periods , may also have a lower risk of developing obesity and type II diabetes at adulthood .
4-1	368-375	Infants	person[16]	giv[16]	_	_
4-2	376-377	,	person[16]	giv[16]	_	_
4-3	378-381	who	person[16]	giv[16]	_	_
4-4	382-386	were	person[16]	giv[16]	_	_
4-5	387-396	breastfed	person[16]	giv[16]	_	_
4-6	397-400	for	person[16]	giv[16]	_	_
4-7	401-407	longer	person[16]|time[17]	giv[16]|new[17]	_	_
4-8	408-415	periods	person[16]|time[17]	giv[16]|new[17]	_	_
4-9	416-417	,	_	_	_	_
4-10	418-421	may	_	_	_	_
4-11	422-426	also	_	_	_	_
4-12	427-431	have	_	_	_	_
4-13	432-433	a	abstract[18]	giv[18]	coref	5-7[25_18]
4-14	434-439	lower	abstract[18]	giv[18]	_	_
4-15	440-444	risk	abstract[18]	giv[18]	_	_
4-16	445-447	of	abstract[18]	giv[18]	_	_
4-17	448-458	developing	abstract[18]	giv[18]	_	_
4-18	459-466	obesity	abstract[18]|abstract	giv[18]|new	_	_
4-19	467-470	and	abstract[18]	giv[18]	_	_
4-20	471-475	type	abstract[18]|abstract[20]|abstract[21]	giv[18]|new[20]|new[21]	coref|coref	5-14[27_20]|5-14[29_21]
4-21	476-478	II	abstract[18]|abstract[20]|abstract[21]	giv[18]|new[20]|new[21]	_	_
4-22	479-487	diabetes	abstract[18]|abstract[21]	giv[18]|new[21]	_	_
4-23	488-490	at	abstract[18]	giv[18]	_	_
4-24	491-500	adulthood	abstract[18]|time	giv[18]|new	_	_
4-25	501-502	.	_	_	_	_

#Text=For mothers , breastfeeding could limit the risk of developing ovarian cancer and type II diabetes .
5-1	503-506	For	_	_	_	_
5-2	507-514	mothers	person	new	coref	6-27
5-3	515-516	,	_	_	_	_
5-4	517-530	breastfeeding	abstract	giv	coref	6-5
5-5	531-536	could	_	_	_	_
5-6	537-542	limit	_	_	_	_
5-7	543-546	the	abstract[25]	giv[25]	_	_
5-8	547-551	risk	abstract[25]	giv[25]	_	_
5-9	552-554	of	abstract[25]	giv[25]	_	_
5-10	555-565	developing	abstract[25]	giv[25]	_	_
5-11	566-573	ovarian	abstract[25]|abstract[26]	giv[25]|new[26]	_	_
5-12	574-580	cancer	abstract[25]|abstract[26]	giv[25]|new[26]	_	_
5-13	581-584	and	abstract[25]	giv[25]	_	_
5-14	585-589	type	abstract[25]|abstract[27]|abstract[29]	giv[25]|giv[27]|giv[29]	coref	19-15[150_29]
5-15	590-592	II	abstract[25]|abstract[27]|person|abstract[29]	giv[25]|giv[27]|new|giv[29]	_	_
5-16	593-601	diabetes	abstract[25]|abstract[29]	giv[25]|giv[29]	_	_
5-17	602-603	.	_	_	_	_

#Text=Despite these benefits , breastfeeding prevalence remains relatively low , particularly in several high-income countries in North America and Europe , where only 40 % of mothers breastfeed six months after delivery .
6-1	604-611	Despite	_	_	_	_
6-2	612-617	these	abstract[30]	giv[30]	_	_
6-3	618-626	benefits	abstract[30]	giv[30]	_	_
6-4	627-628	,	_	_	_	_
6-5	629-642	breastfeeding	abstract|abstract[32]	giv|new[32]	coref	7-2
6-6	643-653	prevalence	abstract[32]	new[32]	_	_
6-7	654-661	remains	_	_	_	_
6-8	662-672	relatively	_	_	_	_
6-9	673-676	low	_	_	_	_
6-10	677-678	,	_	_	_	_
6-11	679-691	particularly	place[33]	new[33]	coref	7-12[45_33]
6-12	692-694	in	place[33]	new[33]	_	_
6-13	695-702	several	place[33]	new[33]	_	_
6-14	703-714	high-income	place[33]	new[33]	_	_
6-15	715-724	countries	place[33]	new[33]	_	_
6-16	725-727	in	place[33]	new[33]	_	_
6-17	728-733	North	place[33]|place[34]	new[33]|new[34]	_	_
6-18	734-741	America	place[33]|place[34]	new[33]|new[34]	_	_
6-19	742-745	and	place[33]	new[33]	_	_
6-20	746-752	Europe	place[33]|place	new[33]|new	_	_
6-21	753-754	,	place[33]	new[33]	_	_
6-22	755-760	where	place[33]	new[33]	_	_
6-23	761-765	only	place[33]|person[36]	new[33]|new[36]	_	_
6-24	766-768	40	place[33]|person[36]	new[33]|new[36]	_	_
6-25	769-770	%	place[33]|person[36]	new[33]|new[36]	_	_
6-26	771-773	of	place[33]|person[36]	new[33]|new[36]	_	_
6-27	774-781	mothers	place[33]|person[36]|person	new[33]|new[36]|giv	coref	13-17[107_0]
6-28	782-792	breastfeed	place[33]	new[33]	_	_
6-29	793-796	six	place[33]|time[38]	new[33]|giv[38]	_	_
6-30	797-803	months	place[33]|time[38]	new[33]|giv[38]	_	_
6-31	804-809	after	place[33]	new[33]	_	_
6-32	810-818	delivery	place[33]|event	new[33]|new	_	_
6-33	819-820	.	_	_	_	_

#Text=Exclusive breastfeeding rate is about 60 % at four months in Scandinavian countries , 35 % in the Netherlands , 16 % in the UK , and 10 % in France .
7-1	821-830	Exclusive	abstract[41]	new[41]	coref	7-5[42_41]
7-2	831-844	breastfeeding	abstract|abstract[41]	giv|new[41]	coref	8-4
7-3	845-849	rate	abstract[41]	new[41]	_	_
7-4	850-852	is	_	_	_	_
7-5	853-858	about	abstract[42]|abstract[43]	giv[42]|giv[43]	coref	7-5[43_42]
7-6	859-861	60	abstract[42]|abstract[43]	giv[42]|giv[43]	_	_
7-7	862-863	%	abstract[42]|abstract[43]	giv[42]|giv[43]	_	_
7-8	864-866	at	abstract[42]|abstract[43]	giv[42]|giv[43]	_	_
7-9	867-871	four	abstract[42]|abstract[43]|time[44]	giv[42]|giv[43]|new[44]	_	_
7-10	872-878	months	abstract[42]|abstract[43]|time[44]	giv[42]|giv[43]|new[44]	_	_
7-11	879-881	in	abstract[42]|abstract[43]	giv[42]|giv[43]	_	_
7-12	882-894	Scandinavian	abstract[42]|abstract[43]|place[45]	giv[42]|giv[43]|giv[45]	coref	19-7[146_45]
7-13	895-904	countries	abstract[42]|abstract[43]|place[45]	giv[42]|giv[43]|giv[45]	_	_
7-14	905-906	,	abstract[43]	giv[43]	_	_
7-15	907-909	35	abstract[43]|abstract[46]	giv[43]|new[46]	coref	9-31[65_46]
7-16	910-911	%	abstract[43]|abstract[46]	giv[43]|new[46]	_	_
7-17	912-914	in	abstract[43]|abstract[46]	giv[43]|new[46]	_	_
7-18	915-918	the	abstract[43]|abstract[46]|place[47]	giv[43]|new[46]|new[47]	_	_
7-19	919-930	Netherlands	abstract[43]|abstract[46]|place[47]	giv[43]|new[46]|new[47]	_	_
7-20	931-932	,	abstract[43]	giv[43]	_	_
7-21	933-935	16	abstract[43]|abstract[48]	giv[43]|new[48]	_	_
7-22	936-937	%	abstract[43]|abstract[48]	giv[43]|new[48]	_	_
7-23	938-940	in	abstract[43]|abstract[48]	giv[43]|new[48]	_	_
7-24	941-944	the	abstract[43]|abstract[48]|place[49]	giv[43]|new[48]|new[49]	_	_
7-25	945-947	UK	abstract[43]|abstract[48]|place[49]	giv[43]|new[48]|new[49]	_	_
7-26	948-949	,	abstract[43]	giv[43]	_	_
7-27	950-953	and	abstract[43]	giv[43]	_	_
7-28	954-956	10	abstract[43]|abstract[50]	giv[43]|new[50]	coref	21-63[186_50]
7-29	957-958	%	abstract[43]|abstract[50]	giv[43]|new[50]	_	_
7-30	959-961	in	_	_	_	_
7-31	962-968	France	place	new	_	_
7-32	969-970	.	_	_	_	_

#Text=Early cessation of breastfeeding clearly is multifactorial .
8-1	971-976	Early	event[52]	new[52]	coref	9-26[63_52]
8-2	977-986	cessation	event[52]	new[52]	_	_
8-3	987-989	of	event[52]	new[52]	_	_
8-4	990-1003	breastfeeding	event[52]|abstract	new[52]|giv	coref	9-29
8-5	1004-1011	clearly	_	_	_	_
8-6	1012-1014	is	_	_	_	_
8-7	1015-1029	multifactorial	_	_	_	_
8-8	1030-1031	.	_	_	_	_

#Text=One of the main factors is the maternal perception of insufficient milk secretion to quell infant ’s hunger or support infant growth and leads to early cessation of breastfeeding in 35 % of cases .
9-1	1032-1035	One	abstract[54]	new[54]	coref	9-7[56_54]
9-2	1036-1038	of	abstract[54]	new[54]	_	_
9-3	1039-1042	the	abstract[54]|abstract[55]	new[54]|new[55]	_	_
9-4	1043-1047	main	abstract[54]|abstract[55]	new[54]|new[55]	_	_
9-5	1048-1055	factors	abstract[54]|abstract[55]	new[54]|new[55]	_	_
9-6	1056-1058	is	_	_	_	_
9-7	1059-1062	the	abstract[56]	giv[56]	_	_
9-8	1063-1071	maternal	abstract[56]	giv[56]	_	_
9-9	1072-1082	perception	abstract[56]	giv[56]	_	_
9-10	1083-1085	of	abstract[56]	giv[56]	_	_
9-11	1086-1098	insufficient	abstract[56]|substance[58]	giv[56]|new[58]	coref	10-29[74_58]
9-12	1099-1103	milk	abstract[56]|substance|substance[58]	giv[56]|new|new[58]	coref	10-4
9-13	1104-1113	secretion	abstract[56]|substance[58]	giv[56]|new[58]	_	_
9-14	1114-1116	to	abstract[56]	giv[56]	_	_
9-15	1117-1122	quell	abstract[56]	giv[56]	_	_
9-16	1123-1129	infant	abstract[56]|animal[59]|abstract[60]	giv[56]|new[59]|new[60]	coref	9-21[0_59]
9-17	1130-1132	’s	abstract[56]|animal[59]|abstract[60]	giv[56]|new[59]|new[60]	_	_
9-18	1133-1139	hunger	abstract[56]|abstract[60]	giv[56]|new[60]	_	_
9-19	1140-1142	or	abstract[56]	giv[56]	_	_
9-20	1143-1150	support	abstract[56]	giv[56]	_	_
9-21	1151-1157	infant	abstract[56]|animal|event[62]	giv[56]|giv|new[62]	coref	12-45[101_0]
9-22	1158-1164	growth	abstract[56]|event[62]	giv[56]|new[62]	_	_
9-23	1165-1168	and	_	_	_	_
9-24	1169-1174	leads	_	_	_	_
9-25	1175-1177	to	_	_	_	_
9-26	1178-1183	early	event[63]	giv[63]	_	_
9-27	1184-1193	cessation	event[63]	giv[63]	_	_
9-28	1194-1196	of	event[63]	giv[63]	_	_
9-29	1197-1210	breastfeeding	event[63]|abstract	giv[63]|giv	coref	11-24
9-30	1211-1213	in	_	_	_	_
9-31	1214-1216	35	abstract[65]	giv[65]	_	_
9-32	1217-1218	%	abstract[65]	giv[65]	_	_
9-33	1219-1221	of	abstract[65]	giv[65]	_	_
9-34	1222-1227	cases	abstract[65]|abstract	giv[65]|new	_	_
9-35	1228-1229	.	_	_	_	_

#Text=Perception of insufficient milk production is a complex , multifactorial issue that can have biological , social , or psychological determinants , and it often remains unclear whether the low milk secretion is real or only perceived .
10-1	1230-1240	Perception	abstract[67]	new[67]	coref	10-7[70_67]
10-2	1241-1243	of	abstract[67]	new[67]	_	_
10-3	1244-1256	insufficient	abstract[67]|abstract[69]	new[67]|new[69]	coref	11-14[78_69]
10-4	1257-1261	milk	abstract[67]|substance|abstract[69]	new[67]|giv|new[69]	coref	10-31
10-5	1262-1272	production	abstract[67]|abstract[69]	new[67]|new[69]	_	_
10-6	1273-1275	is	_	_	_	_
10-7	1276-1277	a	abstract[70]	giv[70]	ana	10-24[0_70]
10-8	1278-1285	complex	abstract[70]	giv[70]	_	_
10-9	1286-1287	,	abstract[70]	giv[70]	_	_
10-10	1288-1302	multifactorial	abstract[70]	giv[70]	_	_
10-11	1303-1308	issue	abstract[70]	giv[70]	_	_
10-12	1309-1313	that	abstract[70]	giv[70]	_	_
10-13	1314-1317	can	abstract[70]	giv[70]	_	_
10-14	1318-1322	have	abstract[70]	giv[70]	_	_
10-15	1323-1333	biological	abstract[70]|abstract[71]	giv[70]|new[71]	_	_
10-16	1334-1335	,	abstract[70]|abstract[71]	giv[70]|new[71]	_	_
10-17	1336-1342	social	abstract[70]|abstract[71]	giv[70]|new[71]	_	_
10-18	1343-1344	,	abstract[70]|abstract[71]	giv[70]|new[71]	_	_
10-19	1345-1347	or	abstract[70]|abstract[71]	giv[70]|new[71]	_	_
10-20	1348-1361	psychological	abstract[70]|abstract[71]	giv[70]|new[71]	_	_
10-21	1362-1374	determinants	abstract[70]|abstract[71]	giv[70]|new[71]	_	_
10-22	1375-1376	,	_	_	_	_
10-23	1377-1380	and	_	_	_	_
10-24	1381-1383	it	abstract	giv	_	_
10-25	1384-1389	often	_	_	_	_
10-26	1390-1397	remains	_	_	_	_
10-27	1398-1405	unclear	_	_	_	_
10-28	1406-1413	whether	_	_	_	_
10-29	1414-1417	the	substance[74]	giv[74]	coref	12-1[87_74]
10-30	1418-1421	low	substance[74]	giv[74]	_	_
10-31	1422-1426	milk	substance|substance[74]	giv|giv[74]	coref	11-15
10-32	1427-1436	secretion	substance[74]	giv[74]	_	_
10-33	1437-1439	is	_	_	_	_
10-34	1440-1444	real	_	_	_	_
10-35	1445-1447	or	_	_	_	_
10-36	1448-1452	only	_	_	_	_
10-37	1453-1462	perceived	_	_	_	_
10-38	1463-1464	.	_	_	_	_

#Text=Indeed , as a result of the lack of an objective marker of insufficient milk production and the importance of maternal psychology in breastfeeding duration , perceived milk insufficiency is probably much more common than true insufficient production .
11-1	1465-1471	Indeed	_	_	_	_
11-2	1472-1473	,	_	_	_	_
11-3	1474-1476	as	_	_	_	_
11-4	1477-1478	a	_	_	_	_
11-5	1479-1485	result	_	_	_	_
11-6	1486-1488	of	_	_	_	_
11-7	1489-1492	the	abstract[75]	new[75]	_	_
11-8	1493-1497	lack	abstract[75]	new[75]	_	_
11-9	1498-1500	of	abstract[75]	new[75]	_	_
11-10	1501-1503	an	abstract[75]|abstract[76]	new[75]|new[76]	_	_
11-11	1504-1513	objective	abstract[75]|abstract[76]	new[75]|new[76]	_	_
11-12	1514-1520	marker	abstract[75]|abstract[76]	new[75]|new[76]	_	_
11-13	1521-1523	of	abstract[75]|abstract[76]	new[75]|new[76]	_	_
11-14	1524-1536	insufficient	abstract[75]|abstract[76]|abstract[78]	new[75]|new[76]|giv[78]	coref	11-36[85_78]
11-15	1537-1541	milk	abstract[75]|abstract[76]|substance|abstract[78]	new[75]|new[76]|giv|giv[78]	coref	11-28
11-16	1542-1552	production	abstract[75]|abstract[76]|abstract[78]	new[75]|new[76]|giv[78]	_	_
11-17	1553-1556	and	abstract[75]	new[75]	_	_
11-18	1557-1560	the	abstract[75]|abstract[79]	new[75]|new[79]	_	_
11-19	1561-1571	importance	abstract[75]|abstract[79]	new[75]|new[79]	_	_
11-20	1572-1574	of	abstract[75]|abstract[79]	new[75]|new[79]	_	_
11-21	1575-1583	maternal	abstract[75]|abstract[79]|abstract[80]	new[75]|new[79]|new[80]	_	_
11-22	1584-1594	psychology	abstract[75]|abstract[79]|abstract[80]	new[75]|new[79]|new[80]	_	_
11-23	1595-1597	in	abstract[75]|abstract[79]	new[75]|new[79]	_	_
11-24	1598-1611	breastfeeding	abstract[75]|abstract[79]|abstract|abstract[82]	new[75]|new[79]|giv|new[82]	coref	13-13[105_0]
11-25	1612-1620	duration	abstract[75]|abstract[79]|abstract[82]	new[75]|new[79]|new[82]	_	_
11-26	1621-1622	,	_	_	_	_
11-27	1623-1632	perceived	abstract[84]	new[84]	_	_
11-28	1633-1637	milk	substance|abstract[84]	giv|new[84]	coref	12-3
11-29	1638-1651	insufficiency	abstract[84]	new[84]	_	_
11-30	1652-1654	is	_	_	_	_
11-31	1655-1663	probably	_	_	_	_
11-32	1664-1668	much	_	_	_	_
11-33	1669-1673	more	_	_	_	_
11-34	1674-1680	common	_	_	_	_
11-35	1681-1685	than	_	_	_	_
11-36	1686-1690	true	abstract[85]	giv[85]	coref	13-2[103_85]
11-37	1691-1703	insufficient	abstract[85]	giv[85]	_	_
11-38	1704-1714	production	abstract[85]	giv[85]	_	_
11-39	1715-1716	.	_	_	_	_

#Text=True insufficient milk secretion can result from many causes , ranging from inability to lactate due to breast abnormalities or endocrine disorder ( 5 % of women ) to difficulties in breastfeeding management , maternal stress and anxiety , or early food diversification in the infant .
12-1	1717-1721	True	substance[87]	giv[87]	_	_
12-2	1722-1734	insufficient	substance[87]	giv[87]	_	_
12-3	1735-1739	milk	substance|substance[87]	giv|giv[87]	coref	13-3
12-4	1740-1749	secretion	substance[87]	giv[87]	_	_
12-5	1750-1753	can	_	_	_	_
12-6	1754-1760	result	_	_	_	_
12-7	1761-1765	from	_	_	_	_
12-8	1766-1770	many	abstract[88]	new[88]	_	_
12-9	1771-1777	causes	abstract[88]	new[88]	_	_
12-10	1778-1779	,	_	_	_	_
12-11	1780-1787	ranging	_	_	_	_
12-12	1788-1792	from	_	_	_	_
12-13	1793-1802	inability	event[89]	new[89]	_	_
12-14	1803-1805	to	event[89]	new[89]	_	_
12-15	1806-1813	lactate	event[89]	new[89]	_	_
12-16	1814-1817	due	event[89]	new[89]	_	_
12-17	1818-1820	to	event[89]	new[89]	_	_
12-18	1821-1827	breast	event[89]|place|abstract[91]	new[89]|new|new[91]	_	_
12-19	1828-1841	abnormalities	event[89]|abstract[91]	new[89]|new[91]	_	_
12-20	1842-1844	or	event[89]	new[89]	_	_
12-21	1845-1854	endocrine	event[89]|abstract[92]	new[89]|new[92]	_	_
12-22	1855-1863	disorder	event[89]|abstract[92]	new[89]|new[92]	_	_
12-23	1864-1865	(	_	_	_	_
12-24	1866-1867	5	abstract[93]	new[93]	_	_
12-25	1868-1869	%	abstract[93]	new[93]	_	_
12-26	1870-1872	of	abstract[93]	new[93]	_	_
12-27	1873-1878	women	abstract[93]|person	new[93]|new	_	_
12-28	1879-1880	)	_	_	_	_
12-29	1881-1883	to	_	_	_	_
12-30	1884-1896	difficulties	abstract[95]	new[95]	_	_
12-31	1897-1899	in	abstract[95]	new[95]	_	_
12-32	1900-1913	breastfeeding	abstract[95]|organization[96]	new[95]|new[96]	_	_
12-33	1914-1924	management	abstract[95]|organization[96]	new[95]|new[96]	_	_
12-34	1925-1926	,	_	_	_	_
12-35	1927-1935	maternal	abstract[97]	new[97]	_	_
12-36	1936-1942	stress	abstract[97]	new[97]	_	_
12-37	1943-1946	and	_	_	_	_
12-38	1947-1954	anxiety	abstract	new	_	_
12-39	1955-1956	,	_	_	_	_
12-40	1957-1959	or	_	_	_	_
12-41	1960-1965	early	abstract[100]	new[100]	_	_
12-42	1966-1970	food	substance|abstract[100]	new|new[100]	_	_
12-43	1971-1986	diversification	abstract[100]	new[100]	_	_
12-44	1987-1989	in	abstract[100]	new[100]	_	_
12-45	1990-1993	the	abstract[100]|animal[101]	new[100]|giv[101]	_	_
12-46	1994-2000	infant	abstract[100]|animal[101]	new[100]|giv[101]	_	_
12-47	2001-2002	.	_	_	_	_

#Text=Although maternal milk production can be often increased through psychological support or maternal breastfeeding education , many healthy mothers are eager to enhance their milk production through various nutritional supplements .
13-1	2003-2011	Although	_	_	_	_
13-2	2012-2020	maternal	abstract[103]	giv[103]	coref	13-24[110_103]
13-3	2021-2025	milk	substance|abstract[103]	giv|giv[103]	coref	13-25
13-4	2026-2036	production	abstract[103]	giv[103]	_	_
13-5	2037-2040	can	_	_	_	_
13-6	2041-2043	be	_	_	_	_
13-7	2044-2049	often	_	_	_	_
13-8	2050-2059	increased	_	_	_	_
13-9	2060-2067	through	_	_	_	_
13-10	2068-2081	psychological	abstract[104]	new[104]	_	_
13-11	2082-2089	support	abstract[104]	new[104]	_	_
13-12	2090-2092	or	_	_	_	_
13-13	2093-2101	maternal	abstract[105]|abstract[106]	giv[105]|new[106]	coref	27-18[0_105]
13-14	2102-2115	breastfeeding	abstract[105]|abstract[106]	giv[105]|new[106]	_	_
13-15	2116-2125	education	abstract[106]	new[106]	_	_
13-16	2126-2127	,	_	_	_	_
13-17	2128-2132	many	person[107]	giv[107]	ana	13-24[0_107]
13-18	2133-2140	healthy	person[107]	giv[107]	_	_
13-19	2141-2148	mothers	person[107]	giv[107]	_	_
13-20	2149-2152	are	_	_	_	_
13-21	2153-2158	eager	_	_	_	_
13-22	2159-2161	to	_	_	_	_
13-23	2162-2169	enhance	_	_	_	_
13-24	2170-2175	their	person|abstract[110]	giv|giv[110]	coref|coref	21-8[169_110]|25-30[219_0]
13-25	2176-2180	milk	substance|abstract[110]	giv|giv[110]	coref	16-13
13-26	2181-2191	production	abstract[110]	giv[110]	_	_
13-27	2192-2199	through	_	_	_	_
13-28	2200-2207	various	substance[111]	new[111]	_	_
13-29	2208-2219	nutritional	substance[111]	new[111]	_	_
13-30	2220-2231	supplements	substance[111]	new[111]	_	_
13-31	2232-2233	.	_	_	_	_

#Text=Several drugs and herbal preparations have traditionally been prescribed as galactologues : i.e. , substances that promote initiation or increase of lactation .
14-1	2234-2241	Several	substance[112]	new[112]	coref	15-1[119_112]
14-2	2242-2247	drugs	substance[112]	new[112]	_	_
14-3	2248-2251	and	_	_	_	_
14-4	2252-2258	herbal	abstract[113]	new[113]	_	_
14-5	2259-2271	preparations	abstract[113]	new[113]	_	_
14-6	2272-2276	have	_	_	_	_
14-7	2277-2290	traditionally	_	_	_	_
14-8	2291-2295	been	_	_	_	_
14-9	2296-2306	prescribed	_	_	_	_
14-10	2307-2309	as	_	_	_	_
14-11	2310-2323	galactologues	substance	new	appos	14-13[115_0]
14-12	2324-2325	:	_	_	_	_
14-13	2326-2330	i.e.	substance[115]	giv[115]	coref	16-4[129_115]
14-14	2331-2332	,	substance[115]	giv[115]	_	_
14-15	2333-2343	substances	substance[115]	giv[115]	_	_
14-16	2344-2348	that	substance[115]	giv[115]	_	_
14-17	2349-2356	promote	substance[115]	giv[115]	_	_
14-18	2357-2367	initiation	substance[115]|event	giv[115]|new	_	_
14-19	2368-2370	or	substance[115]	giv[115]	_	_
14-20	2371-2379	increase	substance[115]|event[117]	giv[115]|new[117]	coref	21-62[187_117]
14-21	2380-2382	of	substance[115]|event[117]	giv[115]|new[117]	_	_
14-22	2383-2392	lactation	substance[115]|event[117]|substance	giv[115]|new[117]|new	coref	16-26
14-23	2393-2394	.	_	_	_	_

#Text=Drugs like domperidone® or metoclopramide® carry the risk of adverse side effects such as arrhythmia or hypothyroidism in mother-children dyad .
15-1	2395-2400	Drugs	substance[119]	giv[119]	_	_
15-2	2401-2405	like	substance[119]	giv[119]	_	_
15-3	2406-2418	domperidone®	substance[119]|substance	giv[119]|new	_	_
15-4	2419-2421	or	substance[119]	giv[119]	_	_
15-5	2422-2437	metoclopramide®	substance[119]|substance	giv[119]|new	_	_
15-6	2438-2443	carry	_	_	_	_
15-7	2444-2447	the	abstract[122]	new[122]	_	_
15-8	2448-2452	risk	abstract[122]	new[122]	_	_
15-9	2453-2455	of	abstract[122]	new[122]	_	_
15-10	2456-2463	adverse	abstract[122]|abstract[124]	new[122]|new[124]	coref	18-20[144_124]
15-11	2464-2468	side	abstract[122]|abstract|abstract[124]	new[122]|new|new[124]	_	_
15-12	2469-2476	effects	abstract[122]|abstract[124]	new[122]|new[124]	_	_
15-13	2477-2481	such	abstract[122]|abstract[124]	new[122]|new[124]	_	_
15-14	2482-2484	as	abstract[122]|abstract[124]	new[122]|new[124]	_	_
15-15	2485-2495	arrhythmia	abstract[122]|abstract[124]|abstract	new[122]|new[124]|new	_	_
15-16	2496-2498	or	abstract[122]|abstract[124]	new[122]|new[124]	_	_
15-17	2499-2513	hypothyroidism	abstract[122]|abstract[124]|abstract[126]	new[122]|new[124]|new[126]	_	_
15-18	2514-2516	in	abstract[122]|abstract[124]|abstract[126]	new[122]|new[124]|new[126]	_	_
15-19	2517-2532	mother-children	abstract[122]|abstract[124]|abstract[126]|abstract[127]	new[122]|new[124]|new[126]|giv[127]	ana	16-1[0_127]
15-20	2533-2537	dyad	abstract[122]|abstract[124]|abstract[126]|abstract[127]	new[122]|new[124]|new[126]|giv[127]	_	_
15-21	2538-2539	.	_	_	_	_

#Text=That is why herbal galactologues like fennel , anise , barley , milk thistle , or garlic are becoming more and more popular for increasing lactation .
16-1	2540-2544	That	abstract	giv	coref	26-12[227_0]
16-2	2545-2547	is	_	_	_	_
16-3	2548-2551	why	_	_	_	_
16-4	2552-2558	herbal	substance[129]	giv[129]	_	_
16-5	2559-2572	galactologues	substance[129]	giv[129]	_	_
16-6	2573-2577	like	substance[129]	giv[129]	_	_
16-7	2578-2584	fennel	substance[129]|substance	giv[129]|new	_	_
16-8	2585-2586	,	substance[129]	giv[129]	_	_
16-9	2587-2592	anise	substance[129]|abstract	giv[129]|new	_	_
16-10	2593-2594	,	substance[129]	giv[129]	_	_
16-11	2595-2601	barley	substance[129]|object	giv[129]|new	_	_
16-12	2602-2603	,	substance[129]	giv[129]	_	_
16-13	2604-2608	milk	substance[129]|substance|plant[134]	giv[129]|giv|new[134]	coref	20-12
16-14	2609-2616	thistle	substance[129]|plant[134]	giv[129]|new[134]	_	_
16-15	2617-2618	,	substance[129]	giv[129]	_	_
16-16	2619-2621	or	substance[129]	giv[129]	_	_
16-17	2622-2628	garlic	substance[129]|plant	giv[129]|new	_	_
16-18	2629-2632	are	_	_	_	_
16-19	2633-2641	becoming	_	_	_	_
16-20	2642-2646	more	_	_	_	_
16-21	2647-2650	and	_	_	_	_
16-22	2651-2655	more	_	_	_	_
16-23	2656-2663	popular	_	_	_	_
16-24	2664-2667	for	_	_	_	_
16-25	2668-2678	increasing	_	_	_	_
16-26	2679-2688	lactation	substance	giv	coref	25-25
16-27	2689-2690	.	_	_	_	_

#Text=Among these herbal compounds , fenugreek probably is the most widely consumed .
17-1	2691-2696	Among	_	_	_	_
17-2	2697-2702	these	substance[137]	new[137]	_	_
17-3	2703-2709	herbal	substance[137]	new[137]	_	_
17-4	2710-2719	compounds	substance[137]	new[137]	_	_
17-5	2720-2721	,	_	_	_	_
17-6	2722-2731	fenugreek	substance	new	coref	18-1
17-7	2732-2740	probably	_	_	_	_
17-8	2741-2743	is	_	_	_	_
17-9	2744-2747	the	_	_	_	_
17-10	2748-2752	most	_	_	_	_
17-11	2753-2759	widely	_	_	_	_
17-12	2760-2768	consumed	_	_	_	_
17-13	2769-2770	.	_	_	_	_

#Text=Fenugreek has been used since antiquity in traditional Persian , Chinese , and Egyptian medicine for its range of therapeutic effects .
18-1	2771-2780	Fenugreek	substance	giv	ana	18-17
18-2	2781-2784	has	_	_	_	_
18-3	2785-2789	been	_	_	_	_
18-4	2790-2794	used	_	_	_	_
18-5	2795-2800	since	_	_	_	_
18-6	2801-2810	antiquity	time	new	_	_
18-7	2811-2813	in	_	_	_	_
18-8	2814-2825	traditional	abstract[141]	new[141]	_	_
18-9	2826-2833	Persian	abstract[141]	new[141]	_	_
18-10	2834-2835	,	abstract[141]	new[141]	_	_
18-11	2836-2843	Chinese	abstract[141]	new[141]	_	_
18-12	2844-2845	,	abstract[141]	new[141]	_	_
18-13	2846-2849	and	abstract[141]	new[141]	_	_
18-14	2850-2858	Egyptian	abstract[141]	new[141]	_	_
18-15	2859-2867	medicine	abstract[141]	new[141]	_	_
18-16	2868-2871	for	_	_	_	_
18-17	2872-2875	its	substance|abstract[143]	giv|new[143]	ana	19-1
18-18	2876-2881	range	abstract[143]	new[143]	_	_
18-19	2882-2884	of	abstract[143]	new[143]	_	_
18-20	2885-2896	therapeutic	abstract[143]|abstract[144]	new[143]|giv[144]	coref	19-10[148_144]
18-21	2897-2904	effects	abstract[143]|abstract[144]	new[143]|giv[144]	_	_
18-22	2905-2906	.	_	_	_	_

#Text=It is now increasingly consumed in Western countries for its presumed protective effects against diabetes , atherosclerosis , inflammation , and hypertriglyceridemia , as well as its putative role as a galactologue due , in part , to trigonelline , one of its main active ingredients .
19-1	2907-2909	It	substance	giv	ana	19-10
19-2	2910-2912	is	_	_	_	_
19-3	2913-2916	now	_	_	_	_
19-4	2917-2929	increasingly	_	_	_	_
19-5	2930-2938	consumed	_	_	_	_
19-6	2939-2941	in	_	_	_	_
19-7	2942-2949	Western	place[146]	giv[146]	_	_
19-8	2950-2959	countries	place[146]	giv[146]	_	_
19-9	2960-2963	for	_	_	_	_
19-10	2964-2967	its	substance|abstract[148]	giv|giv[148]	ana	19-27
19-11	2968-2976	presumed	abstract[148]	giv[148]	_	_
19-12	2977-2987	protective	abstract[148]	giv[148]	_	_
19-13	2988-2995	effects	abstract[148]	giv[148]	_	_
19-14	2996-3003	against	abstract[148]	giv[148]	_	_
19-15	3004-3012	diabetes	abstract[148]|abstract|abstract[150]	giv[148]|new|giv[150]	_	_
19-16	3013-3014	,	abstract[148]|abstract[150]	giv[148]|giv[150]	_	_
19-17	3015-3030	atherosclerosis	abstract[148]|abstract[150]|abstract	giv[148]|giv[150]|new	_	_
19-18	3031-3032	,	abstract[148]|abstract[150]	giv[148]|giv[150]	_	_
19-19	3033-3045	inflammation	abstract[148]|abstract[150]|abstract	giv[148]|giv[150]|new	_	_
19-20	3046-3047	,	abstract[148]|abstract[150]	giv[148]|giv[150]	_	_
19-21	3048-3051	and	abstract[148]|abstract[150]	giv[148]|giv[150]	_	_
19-22	3052-3072	hypertriglyceridemia	abstract[148]|abstract[150]|abstract	giv[148]|giv[150]|new	_	_
19-23	3073-3074	,	abstract[148]|abstract[150]	giv[148]|giv[150]	_	_
19-24	3075-3077	as	abstract[148]|abstract[150]	giv[148]|giv[150]	_	_
19-25	3078-3082	well	abstract[148]|abstract[150]	giv[148]|giv[150]	_	_
19-26	3083-3085	as	abstract[148]|abstract[150]	giv[148]|giv[150]	_	_
19-27	3086-3089	its	abstract[148]|abstract[150]|substance|abstract[155]	giv[148]|giv[150]|giv|new[155]	ana	19-43
19-28	3090-3098	putative	abstract[148]|abstract[150]|abstract[155]	giv[148]|giv[150]|new[155]	_	_
19-29	3099-3103	role	abstract[148]|abstract[150]|abstract[155]	giv[148]|giv[150]|new[155]	_	_
19-30	3104-3106	as	abstract[148]|abstract[150]|abstract[155]	giv[148]|giv[150]|new[155]	_	_
19-31	3107-3108	a	abstract[148]|abstract[150]|abstract[155]|substance[156]	giv[148]|giv[150]|new[155]|new[156]	_	_
19-32	3109-3121	galactologue	abstract[148]|abstract[150]|abstract[155]|substance[156]	giv[148]|giv[150]|new[155]|new[156]	_	_
19-33	3122-3125	due	abstract[148]|abstract[150]|abstract[155]	giv[148]|giv[150]|new[155]	_	_
19-34	3126-3127	,	abstract[148]|abstract[150]|abstract[155]	giv[148]|giv[150]|new[155]	_	_
19-35	3128-3130	in	abstract[148]|abstract[150]|abstract[155]	giv[148]|giv[150]|new[155]	_	_
19-36	3131-3135	part	abstract[148]|abstract[150]|abstract[155]	giv[148]|giv[150]|new[155]	_	_
19-37	3136-3137	,	abstract[148]|abstract[150]|abstract[155]	giv[148]|giv[150]|new[155]	_	_
19-38	3138-3140	to	abstract[148]|abstract[150]|abstract[155]	giv[148]|giv[150]|new[155]	_	_
19-39	3141-3153	trigonelline	abstract[148]|abstract[150]|abstract[155]|substance	giv[148]|giv[150]|new[155]|new	_	_
19-40	3154-3155	,	_	_	_	_
19-41	3156-3159	one	abstract[158]	new[158]	_	_
19-42	3160-3162	of	abstract[158]	new[158]	_	_
19-43	3163-3166	its	abstract[158]|substance|substance[160]	new[158]|giv|new[160]	coref	21-6
19-44	3167-3171	main	abstract[158]|substance[160]	new[158]|new[160]	_	_
19-45	3172-3178	active	abstract[158]|substance[160]	new[158]|new[160]	_	_
19-46	3179-3190	ingredients	abstract[158]|substance[160]	new[158]|new[160]	_	_
19-47	3191-3192	.	_	_	_	_

#Text=There is , however , little evidence for its effectiveness on milk yield .
20-1	3193-3198	There	_	_	_	_
20-2	3199-3201	is	_	_	_	_
20-3	3202-3203	,	_	_	_	_
20-4	3204-3211	however	_	_	_	_
20-5	3212-3213	,	_	_	_	_
20-6	3214-3220	little	abstract[161]	new[161]	ana	20-9[0_161]
20-7	3221-3229	evidence	abstract[161]	new[161]	_	_
20-8	3230-3233	for	abstract[161]	new[161]	_	_
20-9	3234-3237	its	abstract[161]|abstract|abstract[163]	new[161]|giv|new[163]	coref	25-6[211_163]
20-10	3238-3251	effectiveness	abstract[161]|abstract[163]	new[161]|new[163]	_	_
20-11	3252-3254	on	abstract[161]|abstract[163]	new[161]|new[163]	_	_
20-12	3255-3259	milk	abstract[161]|abstract[163]|substance|abstract[165]	new[161]|new[163]|giv|new[165]	coref	21-8
20-13	3260-3265	yield	abstract[161]|abstract[163]|abstract[165]	new[161]|new[163]|new[165]	_	_
20-14	3266-3267	.	_	_	_	_

#Text=Whereas a positive effect of fenugreek on milk production was observed in various mammals , such as rabbit , buffalo , goat , or ewe ; the wide range of doses tested ( from 180 mg . kg-1 . d-1 to 2.1 g. kg-1 . d-1 ) led to large discrepancies in the reported effect on milk production ( ranging from a 10 % increase to a 110 % increase ) , which makes it difficult to determine the effective dose of fenugreek .
21-1	3268-3275	Whereas	_	_	_	_
21-2	3276-3277	a	abstract[166]	new[166]	coref	21-53[183_166]
21-3	3278-3286	positive	abstract[166]	new[166]	_	_
21-4	3287-3293	effect	abstract[166]	new[166]	_	_
21-5	3294-3296	of	abstract[166]	new[166]	_	_
21-6	3297-3306	fenugreek	abstract[166]|substance	new[166]|giv	coref	21-83
21-7	3307-3309	on	abstract[166]	new[166]	_	_
21-8	3310-3314	milk	abstract[166]|substance|abstract[169]	new[166]|giv|giv[169]	coref|coref	21-57|21-57[185_169]
21-9	3315-3325	production	abstract[166]|abstract[169]	new[166]|giv[169]	_	_
21-10	3326-3329	was	_	_	_	_
21-11	3330-3338	observed	_	_	_	_
21-12	3339-3341	in	_	_	_	_
21-13	3342-3349	various	animal[170]	new[170]	_	_
21-14	3350-3357	mammals	animal[170]	new[170]	_	_
21-15	3358-3359	,	animal[170]	new[170]	_	_
21-16	3360-3364	such	animal[170]	new[170]	_	_
21-17	3365-3367	as	animal[170]	new[170]	_	_
21-18	3368-3374	rabbit	animal[170]|animal	new[170]|new	coref	23-20
21-19	3375-3376	,	animal[170]	new[170]	_	_
21-20	3377-3384	buffalo	animal[170]|animal	new[170]|new	_	_
21-21	3385-3386	,	animal[170]	new[170]	_	_
21-22	3387-3391	goat	animal[170]|animal	new[170]|new	_	_
21-23	3392-3393	,	animal[170]	new[170]	_	_
21-24	3394-3396	or	animal[170]	new[170]	_	_
21-25	3397-3400	ewe	animal[170]|animal	new[170]|new	_	_
21-26	3401-3402	;	_	_	_	_
21-27	3403-3406	the	abstract[175]	new[175]	_	_
21-28	3407-3411	wide	abstract[175]	new[175]	_	_
21-29	3412-3417	range	abstract[175]	new[175]	_	_
21-30	3418-3420	of	abstract[175]	new[175]	_	_
21-31	3421-3426	doses	abstract[175]|abstract[176]	new[175]|new[176]	_	_
21-32	3427-3433	tested	abstract[175]|abstract[176]	new[175]|new[176]	_	_
21-33	3434-3435	(	abstract[175]	new[175]	_	_
21-34	3436-3440	from	abstract[175]	new[175]	_	_
21-35	3441-3444	180	abstract[175]|substance[177]	new[175]|new[177]	_	_
21-36	3445-3447	mg	abstract[175]|substance[177]	new[175]|new[177]	_	_
21-37	3448-3449	.	_	_	_	_
21-38	3450-3454	kg-1	event	new	_	_
21-39	3455-3456	.	_	_	_	_
21-40	3457-3460	d-1	_	_	_	_
21-41	3461-3463	to	_	_	_	_
21-42	3464-3467	2.1	abstract[179]|abstract[180]	new[179]|new[180]	_	_
21-43	3468-3470	g.	abstract[179]|abstract[180]	new[179]|new[180]	_	_
21-44	3471-3475	kg-1	abstract[180]	new[180]	_	_
21-45	3476-3477	.	abstract[180]	new[180]	_	_
21-46	3478-3481	d-1	abstract[180]|abstract	new[180]|new	_	_
21-47	3482-3483	)	_	_	_	_
21-48	3484-3487	led	_	_	_	_
21-49	3488-3490	to	_	_	_	_
21-50	3491-3496	large	abstract[182]	new[182]	_	_
21-51	3497-3510	discrepancies	abstract[182]	new[182]	_	_
21-52	3511-3513	in	abstract[182]	new[182]	_	_
21-53	3514-3517	the	abstract[182]|abstract[183]	new[182]|giv[183]	coref	22-8[194_183]
21-54	3518-3526	reported	abstract[182]|abstract[183]	new[182]|giv[183]	_	_
21-55	3527-3533	effect	abstract[182]|abstract[183]	new[182]|giv[183]	_	_
21-56	3534-3536	on	abstract[182]|abstract[183]	new[182]|giv[183]	_	_
21-57	3537-3541	milk	abstract[182]|abstract[183]|substance|abstract[185]	new[182]|giv[183]|giv|giv[185]	ana|coref	21-75[0_185]|23-5
21-58	3542-3552	production	abstract[182]|abstract[183]|abstract[185]	new[182]|giv[183]|giv[185]	_	_
21-59	3553-3554	(	abstract[182]	new[182]	_	_
21-60	3555-3562	ranging	abstract[182]	new[182]	_	_
21-61	3563-3567	from	abstract[182]	new[182]	_	_
21-62	3568-3569	a	abstract[182]|event[187]	new[182]|giv[187]	coref	21-67[189_187]
21-63	3570-3572	10	abstract[182]|abstract[186]|event[187]	new[182]|giv[186]|giv[187]	_	_
21-64	3573-3574	%	abstract[182]|abstract[186]|event[187]	new[182]|giv[186]|giv[187]	_	_
21-65	3575-3583	increase	abstract[182]|event[187]	new[182]|giv[187]	_	_
21-66	3584-3586	to	abstract[182]|event[187]	new[182]|giv[187]	_	_
21-67	3587-3588	a	abstract[182]|event[187]|event[189]	new[182]|giv[187]|giv[189]	_	_
21-68	3589-3592	110	abstract[182]|event[187]|abstract[188]|event[189]	new[182]|giv[187]|new[188]|giv[189]	_	_
21-69	3593-3594	%	abstract[182]|event[187]|abstract[188]|event[189]	new[182]|giv[187]|new[188]|giv[189]	_	_
21-70	3595-3603	increase	abstract[182]|event[187]|event[189]	new[182]|giv[187]|giv[189]	_	_
21-71	3604-3605	)	abstract[182]	new[182]	_	_
21-72	3606-3607	,	abstract[182]	new[182]	_	_
21-73	3608-3613	which	abstract[182]	new[182]	_	_
21-74	3614-3619	makes	abstract[182]	new[182]	_	_
21-75	3620-3622	it	abstract[182]|abstract	new[182]|giv	coref	23-5[199_0]
21-76	3623-3632	difficult	abstract[182]	new[182]	_	_
21-77	3633-3635	to	abstract[182]	new[182]	_	_
21-78	3636-3645	determine	abstract[182]	new[182]	_	_
21-79	3646-3649	the	abstract[182]|abstract[191]	new[182]|new[191]	_	_
21-80	3650-3659	effective	abstract[182]|abstract[191]	new[182]|new[191]	_	_
21-81	3660-3664	dose	abstract[182]|abstract[191]	new[182]|new[191]	_	_
21-82	3665-3667	of	abstract[182]|abstract[191]	new[182]|new[191]	_	_
21-83	3668-3677	fenugreek	abstract[182]|abstract[191]|substance	new[182]|new[191]|giv	coref	25-9[212_0]
21-84	3678-3679	.	_	_	_	_

#Text=Moreover , other studies failed to demonstrate an effect in rabbits and goats .
22-1	3680-3688	Moreover	_	_	_	_
22-2	3689-3690	,	_	_	_	_
22-3	3691-3696	other	abstract[193]	new[193]	coref	23-2[197_193]
22-4	3697-3704	studies	abstract[193]	new[193]	_	_
22-5	3705-3711	failed	_	_	_	_
22-6	3712-3714	to	_	_	_	_
22-7	3715-3726	demonstrate	_	_	_	_
22-8	3727-3729	an	abstract[194]	giv[194]	_	_
22-9	3730-3736	effect	abstract[194]	giv[194]	_	_
22-10	3737-3739	in	abstract[194]	giv[194]	_	_
22-11	3740-3747	rabbits	abstract[194]|animal	giv[194]|new	_	_
22-12	3748-3751	and	abstract[194]	giv[194]	_	_
22-13	3752-3757	goats	abstract[194]|animal	giv[194]|new	_	_
22-14	3758-3759	.	_	_	_	_

#Text=In these studies , milk production was measured either by the weight – suckle – weight method ( in rabbit ) , or by milking ( in larger animals ) .
23-1	3760-3762	In	_	_	_	_
23-2	3763-3768	these	abstract[197]	giv[197]	coref	25-3[210_197]
23-3	3769-3776	studies	abstract[197]	giv[197]	_	_
23-4	3777-3778	,	_	_	_	_
23-5	3779-3783	milk	substance|abstract[199]	giv|giv[199]	coref|coref	24-11|24-11[207_199]
23-6	3784-3794	production	abstract[199]	giv[199]	_	_
23-7	3795-3798	was	_	_	_	_
23-8	3799-3807	measured	_	_	_	_
23-9	3808-3814	either	abstract[202]	new[202]	_	_
23-10	3815-3817	by	abstract[202]	new[202]	_	_
23-11	3818-3821	the	abstract[202]	new[202]	_	_
23-12	3822-3828	weight	abstract|abstract[202]	new|new[202]	_	_
23-13	3829-3830	–	abstract[202]	new[202]	_	_
23-14	3831-3837	suckle	abstract[202]	new[202]	_	_
23-15	3838-3839	–	abstract[202]	new[202]	_	_
23-16	3840-3846	weight	abstract|abstract[202]	new|new[202]	_	_
23-17	3847-3853	method	abstract[202]	new[202]	_	_
23-18	3854-3855	(	abstract[202]	new[202]	_	_
23-19	3856-3858	in	abstract[202]	new[202]	_	_
23-20	3859-3865	rabbit	abstract[202]|animal	new[202]|giv	_	_
23-21	3866-3867	)	abstract[202]	new[202]	_	_
23-22	3868-3869	,	_	_	_	_
23-23	3870-3872	or	_	_	_	_
23-24	3873-3875	by	_	_	_	_
23-25	3876-3883	milking	_	_	_	_
23-26	3884-3885	(	_	_	_	_
23-27	3886-3888	in	_	_	_	_
23-28	3889-3895	larger	animal[204]	new[204]	_	_
23-29	3896-3903	animals	animal[204]	new[204]	_	_
23-30	3904-3905	)	_	_	_	_
23-31	3906-3907	.	_	_	_	_

#Text=The latter methods do not , however , directly assess milk production in response to physiological suckling by the pups .
24-1	3908-3911	The	abstract[205]	new[205]	_	_
24-2	3912-3918	latter	abstract[205]	new[205]	_	_
24-3	3919-3926	methods	abstract[205]	new[205]	_	_
24-4	3927-3929	do	_	_	_	_
24-5	3930-3933	not	_	_	_	_
24-6	3934-3935	,	_	_	_	_
24-7	3936-3943	however	_	_	_	_
24-8	3944-3945	,	_	_	_	_
24-9	3946-3954	directly	_	_	_	_
24-10	3955-3961	assess	_	_	_	_
24-11	3962-3966	milk	substance|abstract[207]	giv|giv[207]	coref|coref	25-12|25-12[214_207]
24-12	3967-3977	production	abstract[207]	giv[207]	_	_
24-13	3978-3980	in	_	_	_	_
24-14	3981-3989	response	_	_	_	_
24-15	3990-3992	to	_	_	_	_
24-16	3993-4006	physiological	event[208]	new[208]	_	_
24-17	4007-4015	suckling	event[208]	new[208]	_	_
24-18	4016-4018	by	event[208]	new[208]	_	_
24-19	4019-4022	the	event[208]|animal[209]	new[208]|new[209]	_	_
24-20	4023-4027	pups	event[208]|animal[209]	new[208]|new[209]	_	_
24-21	4028-4029	.	_	_	_	_

#Text=Moreover , these studies evaluated the effectiveness of fenugreek to increase milk production with the aim of productivity , under otherwise optimal conditions of lactation , as opposed to mothers challenged by their perception of insufficient milk production .
25-1	4030-4038	Moreover	_	_	_	_
25-2	4039-4040	,	_	_	_	_
25-3	4041-4046	these	abstract[210]	giv[210]	coref	26-5[225_210]
25-4	4047-4054	studies	abstract[210]	giv[210]	_	_
25-5	4055-4064	evaluated	_	_	_	_
25-6	4065-4068	the	abstract[211]	giv[211]	_	_
25-7	4069-4082	effectiveness	abstract[211]	giv[211]	_	_
25-8	4083-4085	of	abstract[211]	giv[211]	_	_
25-9	4086-4095	fenugreek	abstract[211]|substance[212]	giv[211]|giv[212]	coref	26-15[0_212]
25-10	4096-4098	to	abstract[211]|substance[212]	giv[211]|giv[212]	_	_
25-11	4099-4107	increase	abstract[211]|substance[212]	giv[211]|giv[212]	_	_
25-12	4108-4112	milk	abstract[211]|substance[212]|substance|abstract[214]	giv[211]|giv[212]|giv|giv[214]	coref|coref	25-37|25-36[223_214]
25-13	4113-4123	production	abstract[211]|substance[212]|abstract[214]	giv[211]|giv[212]|giv[214]	_	_
25-14	4124-4128	with	abstract[211]|substance[212]	giv[211]|giv[212]	_	_
25-15	4129-4132	the	abstract[211]|substance[212]|abstract[215]	giv[211]|giv[212]|new[215]	_	_
25-16	4133-4136	aim	abstract[211]|substance[212]|abstract[215]	giv[211]|giv[212]|new[215]	_	_
25-17	4137-4139	of	abstract[211]|substance[212]|abstract[215]	giv[211]|giv[212]|new[215]	_	_
25-18	4140-4152	productivity	abstract[211]|substance[212]|abstract[215]|abstract	giv[211]|giv[212]|new[215]|new	_	_
25-19	4153-4154	,	abstract[211]|substance[212]	giv[211]|giv[212]	_	_
25-20	4155-4160	under	abstract[211]|substance[212]	giv[211]|giv[212]	_	_
25-21	4161-4170	otherwise	abstract[211]|substance[212]|abstract[217]	giv[211]|giv[212]|new[217]	_	_
25-22	4171-4178	optimal	abstract[211]|substance[212]|abstract[217]	giv[211]|giv[212]|new[217]	_	_
25-23	4179-4189	conditions	abstract[211]|substance[212]|abstract[217]	giv[211]|giv[212]|new[217]	_	_
25-24	4190-4192	of	abstract[211]|substance[212]|abstract[217]	giv[211]|giv[212]|new[217]	_	_
25-25	4193-4202	lactation	abstract[211]|substance[212]|abstract[217]|substance	giv[211]|giv[212]|new[217]|giv	_	_
25-26	4203-4204	,	_	_	_	_
25-27	4205-4207	as	_	_	_	_
25-28	4208-4215	opposed	_	_	_	_
25-29	4216-4218	to	_	_	_	_
25-30	4219-4226	mothers	person[219]	giv[219]	ana	25-33[0_219]
25-31	4227-4237	challenged	person[219]	giv[219]	_	_
25-32	4238-4240	by	person[219]	giv[219]	_	_
25-33	4241-4246	their	person[219]|person|abstract[221]	giv[219]|giv|new[221]	_	_
25-34	4247-4257	perception	person[219]|abstract[221]	giv[219]|new[221]	_	_
25-35	4258-4260	of	person[219]|abstract[221]	giv[219]|new[221]	_	_
25-36	4261-4273	insufficient	person[219]|abstract[221]|abstract[223]	giv[219]|new[221]|giv[223]	ana	26-3[224_223]
25-37	4274-4278	milk	person[219]|abstract[221]|substance|abstract[223]	giv[219]|new[221]|giv|giv[223]	coref	27-9
25-38	4279-4289	production	person[219]|abstract[221]|abstract[223]	giv[219]|new[221]|giv[223]	_	_
25-39	4290-4291	.	_	_	_	_

#Text=Finally , none of these studies evaluated the metabolic status of mother-infant dyad following fenugreek supplementation .
26-1	4292-4299	Finally	_	_	_	_
26-2	4300-4301	,	_	_	_	_
26-3	4302-4306	none	abstract[224]	giv[224]	coref	27-9[233_224]
26-4	4307-4309	of	abstract[224]	giv[224]	_	_
26-5	4310-4315	these	abstract[224]|abstract[225]	giv[224]|giv[225]	_	_
26-6	4316-4323	studies	abstract[224]|abstract[225]	giv[224]|giv[225]	_	_
26-7	4324-4333	evaluated	_	_	_	_
26-8	4334-4337	the	abstract[226]	new[226]	_	_
26-9	4338-4347	metabolic	abstract[226]	new[226]	_	_
26-10	4348-4354	status	abstract[226]	new[226]	_	_
26-11	4355-4357	of	abstract[226]	new[226]	_	_
26-12	4358-4371	mother-infant	abstract[226]|abstract[227]	new[226]|giv[227]	_	_
26-13	4372-4376	dyad	abstract[226]|abstract[227]	new[226]|giv[227]	_	_
26-14	4377-4386	following	_	_	_	_
26-15	4387-4396	fenugreek	substance|substance[229]	giv|new[229]	coref	27-7
26-16	4397-4412	supplementation	substance[229]	new[229]	_	_
26-17	4413-4414	.	_	_	_	_

#Text=Thus , the true efficacy of fenugreek on milk production in an animal model submitted to a breastfeeding challenge remains to be ascertained .
27-1	4415-4419	Thus	_	_	_	_
27-2	4420-4421	,	_	_	_	_
27-3	4422-4425	the	abstract[230]	new[230]	_	_
27-4	4426-4430	true	abstract[230]	new[230]	_	_
27-5	4431-4439	efficacy	abstract[230]	new[230]	_	_
27-6	4440-4442	of	abstract[230]	new[230]	_	_
27-7	4443-4452	fenugreek	abstract[230]|substance	new[230]|giv	_	_
27-8	4453-4455	on	abstract[230]	new[230]	_	_
27-9	4456-4460	milk	abstract[230]|substance|abstract[233]	new[230]|giv|giv[233]	_	_
27-10	4461-4471	production	abstract[230]|abstract[233]	new[230]|giv[233]	_	_
27-11	4472-4474	in	abstract[230]|abstract[233]	new[230]|giv[233]	_	_
27-12	4475-4477	an	abstract[230]|abstract[233]|abstract[235]	new[230]|giv[233]|new[235]	_	_
27-13	4478-4484	animal	abstract[230]|abstract[233]|animal|abstract[235]	new[230]|giv[233]|new|new[235]	_	_
27-14	4485-4490	model	abstract[230]|abstract[233]|abstract[235]	new[230]|giv[233]|new[235]	_	_
27-15	4491-4500	submitted	abstract[230]|abstract[233]|abstract[235]	new[230]|giv[233]|new[235]	_	_
27-16	4501-4503	to	abstract[230]|abstract[233]|abstract[235]	new[230]|giv[233]|new[235]	_	_
27-17	4504-4505	a	abstract[230]|abstract[233]|abstract[235]|abstract[237]	new[230]|giv[233]|new[235]|new[237]	_	_
27-18	4506-4519	breastfeeding	abstract[230]|abstract[233]|abstract[235]|abstract|abstract[237]	new[230]|giv[233]|new[235]|giv|new[237]	_	_
27-19	4520-4529	challenge	abstract[230]|abstract[233]|abstract[235]|abstract[237]	new[230]|giv[233]|new[235]|new[237]	_	_
27-20	4530-4537	remains	_	_	_	_
27-21	4538-4540	to	_	_	_	_
27-22	4541-4543	be	_	_	_	_
27-23	4544-4555	ascertained	_	_	_	_
27-24	4556-4557	.	_	_	_	_
